Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 23
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines

  • Fuentes-Valverde, Víctor
  • García, Patricia
  • Candela, Ana
  • Santamarina-Fernández, Rebeca
  • Avendaño-Ortiz, José
  • Martínez-Alonso, Emma
  • Oviaño, Marina
  • Cantón, Rafael
  • Arenas, Jesús
  • Moscoso, Miriam
  • Bou, Germán
[Abstract] Introduction: Pseudomonas aeruginosa is a highly adaptable Gram-negative bacterium causing severe respiratory infections, particularly in vulnerable populations. The rise of antimicrobial resistance highlights the urgent need for effective vaccines. We previously developed a live-attenuated vaccine candidate, PAO1 ΔmurI Δalr ΔdadX, a genetically stable double auxotrophic strain that exhibited dose-dependent reactogenicity upon intranasal administration in mice, likely due to lipid A component of lipopolysaccharide (LPS). Methods: To reduce LPS-associated toxicity while preserving immunogenicity, we engineered novel strains by inactivating genes involved in lipid A biosynthesis (htrB1, htrB2) or modification (pagP, pagL). Lipid A structural modifications were confirmed by MALDI-TOF MS. Mutants were evaluated for Toll-like receptor 4 (TLR4) activation, virulence attenuation, and their ability to induce immune responses and protection in an acute pneumonia model. Results: All engineered strains displayed modified lipid A structures. Mutations in htrB1 and htrB2 reduced TLR4 activation and significantly attenuated virulence following intraperitoneal challenge in mice. Inactivation of pagL resulted in minimal attenuation, whereas pagP inactivation led to marked attenuation without altering TLR4 activation. In the acute pneumonia model, all mutants elicited robust systemic and mucosal immune responses, and conferred strong protection, despite transient weight loss following intranasal administration. Discussion: Targeted lipid A modification represents an effective strategy to reduce in vitro reactogenicity while preserving immunogenicity in live-attenuated P. aeruginosa vaccine candidates. Although further optimization may minimize residual in vivo effects, these findings support the potential of engineered strains as vaccine candidates for preventing respiratory infections caused by P. aeruginosa., The author(s) declared that financial support was received for this work and/or its publication. This work was supported by a grant from the SERGAS-Galician Healthcare Service (Program “Innova Saúde”), CIBERINFEC, and the projects PI18/00501 and PI21/00704 to GB, and the project PI20/00686 to MO, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 from the Ministry of Economy and Competitiveness and the Institute of Health Carlos III. In addition, this work was supported by the Ciencia e Innovación/Agencia Española de Investigación MCIN/AEI/10.13039/501100011033 and, as appropriate, by ERDF A way of making Europe by the European Union or by the European Union Next Generation EU/PRTR (Grant agreement PID2020-114617RB-100) to JA. VF-V was funded with a predoctoral fellowship from the Conselleria de Cultura, Xunta de Galicia (IN606A-2019/012) and by the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) for a research stay (May-July 2022) at the University of Zaragoza. AC was financially supported by the Río Hortega program (ISCIII-SERGAS, CM21/00165).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Global transcriptomic analysis during murine pneumonia infection reveals new virulence factors in Acinetobacter baumannii

  • Martínez Guitián, Marta
  • Vázquez-Ucha, Juan Carlos
  • Álvarez-Fraga, Laura
  • Conde-Pérez, Kelly
  • Vallejo, J. A.
  • Perina Cedrón, Alejandra
  • Bou, Germán
  • Poza, Margarita
  • Beceiro Casas, Alejandro
[Abstract] Background: Infections caused by multidrug-resistant pathogens such as Acinetobacter baumannii constitute a major health problem worldwide. In this study we present a global in vivo transcriptomic analysis of A. baumannii isolated from the lungs of mice with pneumonia infection. Methods: Mice were infected with A. baumannii ATCC 17978 and AbH12O-A2 strains and the total bacterial RNA were analyzed by RNA sequencing. Lists of differentially expressed genes were obtained and 14 of them were selected for gene deletion and further analysis. Results: Transcriptomic analysis revealed a specific gene expression profile in A. baumannii during lung infection with upregulation of genes involved in iron acquisition and host invasion. Mutant strains lacking feoA, mtnN, yfgC, basB, hisF, oatA, and bfnL showed a significant loss of virulence in murine pneumonia. A decrease in biofilm formation, adherence to human epithelial cells, and growth rate was observed in selected mutants. Conclusions: This study provides an insight into A. baumannii gene expression profile during murine pneumonia infection. Data revealed that 7 in vivo upregulated genes were involved in virulence and could be considered new therapeutic targets., This work was supported by Instituto de Salud Carlos III (PI15/00860 and PI18/00501 to G. B. and PI14/00059 and PI17/01482 to A. B. and M. P.); Axencia Galega de Innovacion- Consellería de Economía, Emprego e Industria (IN607A 2016/22 to G. B); Spanish Network for Research in Infectious Diseases and European Development Regional Fund (REIPI RD16/0016/006 and FI18/00315 to J. C. V.-U); M. M.-G. was supported by the Spanish Society of Clinical Microbiology and Infectious Diseases (Clara Roy grant); and K. C.-P. was supported by the Spanish Association Against Cancer.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Carbapenem Resistance in Acinetobacter nosocomialis and Acinetobacter junii Conferred by Acquisition of blaOXA-24/40 and Genetic Characterization of the Transmission Mechanism between Acinetobacter Genomic Species

  • Lasarte-Monterrubio, Cristina
  • Guijarro, Paula
  • Bellés, Alba
  • Vázquez-Ucha, Juan Carlos
  • Arca-Suárez, Jorge
  • Fernández-Lozano, Carlos
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Carbapenem resistance is increasing among Gram-negative bacteria, including the genus Acinetobacter. This study aimed to characterize, for the first time, the development of carbapenem resistance in clinical isolates of Acinetobacter junii and Acinetobacter nosocomialis conferred by the acquisition of a plasmid-borne blaOXA-24/40 gene and also to characterize the dissemination of this gene between species of Acinetobacter. Carbapenem-resistant A. nosocomialis HUAV-AN66 and A. junii HUAV-AJ77 strains were isolated in the Arnau de Vilanova Hospital (Spain). The genomes were sequenced, and in silico analysis were performed to characterize the genetic environment and the OXA-24/40 transmission mechanism. Antibiotic MICs were determined, and horizontal transfer assays were conducted to evaluate interspecies transmission of OXA-24/40. Carbapenems MICs obtained were ≥64 mg/L for HUAV-AN66 and HUAV-AJ77. Genome analysis revealed the presence in both strains of a new plasmid, designated pHUAV/OXA-24/40, harboring the carbapenem-resistance gene blaOXA-24/40 and flanked by sequences XerC/XerD. pHUAV/OXA-24/40 was successfully transferred from A. nosocomialis and A. junii to a carbapenem-susceptible A. baumannii strain, thus conferring carbapenem resistance. A second plasmid (pHUAV/AMG-R) was identified in both clinical isolates for the successful horizontal transfer of pHUAV/OXA-24/40. blaOXA-24/40-carrying plasmids of the GR12 group and showing high identity with pHUAV/OXA-24/40 were identified in at least 8 Acinetobacter species. In conclusion the carbapenemase OXA-24/40 is described for the first time in A. nosocomialis and A. junii. In both isolates the blaOXA-24/40 gene was located in the GR12 pHUAV/OXA-24/40 plasmid. GR12 plasmids are implicated in the dissemination and spread of carbapenem resistance among Acinetobacter species. IMPORTANCE Acinetobacter baumannii is one of the most relevant pathogens in terms of antibiotic resistance. The main resistance mechanisms are the carbapenem-hydrolyzing class D β-lactamases (CHDLs), especially OXA-23 and OXA-24/40. In addition to A. baumannii, there are other species within the genus Acinetobacter, which in general exhibit much lower resistance rates. In this work we characterize for the first time two clinical isolates of Acinetobacter nosocomialis and Acinetobacter junii, isolated in the same hospital, carrying the carbapenemase OXA-24/40 and displaying high resistance rates to carbapenems. By means of bioinformatics analysis we have also been able to characterize the mechanism by which this carbapenemase is horizontally transferred interspecies of Acinetobacter spp. The dissemination of carbapenemase OXA-24/40 between non-baumannii Acinetobacter species is concerning since it prevents the use of most β-lactam antibiotics in the fight against these resistant isolates., This work was supported by Projects PI17/01482 and PI20/01212 awarded to A.B. and PI18/00501 to G.B., all within in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII - General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The work was also supported by CIBERINF (CIBER de Enfermedades Infecciosas). The study was also funded by project IN607A 2020/05 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) awarded to G.B. and IN607D 2021/12 awarded to A.B. This work was also supported by Planes Nacionales de I+D+i2008 to 2011/2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectiosus Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. J.A.-S.was financially supported by the Rio Hortega program (ISCIII, CM19/00219), J.C.V.-U. was financially supported by the pFIS program (ISCIII, PI17/01482), C.L.-M. was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and P.G.-S. was financially supported by IN607A 2020/05 Grant (Xunta de Galicia), Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606A-2019/029
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

LpxR and PagL expression in live attenuated auxotrophic Pseudomonas aeruginosa vaccines modulates lipid A reactogenicity in vitro while preserving immunogenicity

  • Moscoso, Miriam
  • Fuentes-Valverde, Víctor
  • García, Patricia
  • Vallejo, J. A.
  • Pérez-Ortega, Jesús
  • Santamarina-Fernández, Rebeca
  • Candela, Ana
  • Oviaño, Marina
  • Arenas, Jesús
  • Bou, Germán
[Abstract] Introduction: Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen responsible for severe respiratory tract infections. We previously developed a live attenuated auxotrophic vaccine candidate, PAO1 ΔmurI, which conferred protection in murine infection models but exhibited significant reactogenicity when administered intranasally. To reduce the toxicity of PAO1 ΔmurI without compromising its protective efficacy, we engineered strains with a modified lipid A structure, as lipid A is one of the main toxic components of whole-cell vaccines. Methods: Two lipid A-modifying enzymes, LpxR and PagL were overproduced in PAO1 ΔmurI derivatives. The resulting lipopolysaccharide (LPS) was analyzed by MALDI-TOF mass spectrometry. In vitro assays with HEK293-Blue reporter cells expressing murine and human Toll-like receptor 4 (TLR4) were used to assess LPS-associated toxicity, while in vivo reactogenicity and protective efficacy were evaluated in a murine acute pneumonia model. Results: LPS extracted from the wild-type strain showed heterogeneous lipid A structures with varying degrees of acylation, and a predominant penta-acylated species. Expression of LpxR led to enrichment in tetra-acylated species, while PagL expression reduced the heterogeneity observed in the wild type. Both mutant strains showed decreased TLR4 activation in vitro as compared to the wild type. In mice, lipid A-modified derivatives retained protective efficacy; however, no reduction in reactogenicity was observed. Discussion: Lipid A modifications mediated by LpxR and PagL attenuated TLR4 signaling in vitro but were insufficient to reduce in vivo reactogenicity. Additional modifications or targeting of other toxic components may be required. This strategy may serve as an initial basis for optimizing live attenuated P. aeruginosa vaccines, although additional approaches will likely be necessary to achieve substantial improvements., This work was supported by a grant from the SERGAS-Galician Healthcare Service (Program “Innova Saúde”), CIBERINFEC, and the projects PI18/00501 and PI21/00704 to G.B., and the project PI20/00686 to M.O., integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 from the Ministry of Economy and Competitiveness and the Institute of Health Carlos III. In addition, this work was supported by the Ciencia e Innovación/Agencia Española de Investigación MCIN/AEI/10.13039/501100011033 and, as appropriate, by ERDF A way of making Europe by the European Union or by the European Union Next Generation EU/PRTR (Grant agreement PID2020-114617RB-100) to J.A. V.F-V. was funded with a predoctoral fellowship from Conselleria de Cultura, Xunta de Galicia (IN606A-2019/012). A.C. was financially supported by the Río Hortega program (ISCIII-SERGAS, CM21/00165).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Antisense inhibition of lpxB gene expression in Acinetobacter baumannii by peptide-PNA conjugates and synergy with colistin

  • Martínez Guitián, Marta
  • Vázquez-Ucha, Juan Carlos
  • Álvarez-Fraga, Laura
  • Conde-Pérez, Kelly
  • Bou, Germán
  • Poza, Margarita
  • Beceiro Casas, Alejandro
[Abstract] Background: LpxB is an enzyme involved in the biosynthesis pathway of lipid A, a component of LPS. Objectives: To evaluate the lpxB gene in Acinetobacter baumannii as a potential therapeutic target and to propose antisense agents such as peptide nucleic acids (PNAs) as a tool to combat bacterial infection, either alone or in combination with known antimicrobial therapies. Methods: RNA-seq analysis of the A. baumannii ATCC 17978 strain in a murine pneumonia model was performed to study the in vivo expression of lpxB. Protein expression was studied in the presence or absence of anti-lpxB (KFF)3K-PNA (pPNA). Time-kill curve analyses and protection assays of infected A549 cells were performed. The chequerboard technique was used to test for synergy between pPNA and colistin. A Galleria mellonella infection model was used to test the in vivo efficacy of pPNA. Results: The lpxB gene was overexpressed during pneumonia. Treatment with a specific pPNA inhibited LpxB expression in vitro, decreased survival of the ATCC 17978 strain and increased the survival rate of infected A549 cells. Synergy was observed between pPNA and colistin in colistin-susceptible strains. In vivo assays confirmed that a combination treatment of anti-lpxB pPNA and colistin was more effective than colistin in monotherapy. Conclusions: The lpxB gene is essential for A. baumannii survival. Anti-lpxB pPNA inhibits LpxB expression, causing bacterial death. This pPNA showed synergy with colistin and increased the survival rate in G. mellonella. The data suggest that antisense pPNA molecules blocking the lpxB gene could be used as antibacterial agents., This study was funded by projects PI15/00860 and PI18/00501 to G.B., CP13/00226 to A.B., and PI14/00059 and PI17/01482 to A.B. and M.P. (Instituto de Salud Carlos III). The study was also funded by project IN607A 2016/22 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) to G.B. Support was also provided by Planes Nacionales de I + D+i 2013–2016 and ISCIII, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by European Development Regional Fund ‘A way to achieve Europe’ and the operative programme Intelligent Growth 2014–2020. J.C.V.U. was financially supported by the Miguel Servet Programme (ISCIII, Spain CP13/00226) and the pFIS Programme (FI18/00315) and M.M.G. was financially supported by a Clara Roy grant (SEIMC) and K.C.P. by IN607A 2016/22.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Selection of AmpC β-Lactamase variants and Metallo-β-Lactamases leading to Ceftolozane/Tazobactam and Ceftazidime/Avibactam resistance during treatment of MDR/XDR Pseudomonas aeruginosa infections

  • Ruedas-López, Alba
  • Alonso-García, Isaac
  • Lasarte-Monterrubio, Cristina
  • Guijarro-Sánchez, Paula
  • Gato, Eva
  • Vázquez-Ucha, Juan Carlos
  • Vallejo, J. A.
  • Fraile-Ribot, Pablo Arturo
  • Fernández-Pérez, Begoña
  • Velasco, David
  • Gutiérrez-Urbón, José María
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Oliver, Antonio
  • Arca-Suárez, Jorge
  • Bou, Germán
[Abstract] Infections caused by ceftolozane-tazobactam and ceftazidime-avibactam-resistant P. aeruginosa infections are an emerging concern. We aimed to analyze the underlying ceftolozane-tazobactam and ceftazidime-avibactam resistance mechanisms in all multidrug-resistant or extensively drug-resistant (MDR/XDR) P. aeruginosa isolates recovered during 1 year (2020) from patients with a documented P. aeruginosa infection. Fifteen isolates showing ceftolozane-tazobactam and ceftazidime-avibactam resistance were evaluated. Clinical conditions, previous positive cultures, and β-lactams received in the previous month were reviewed for each patient. MICs were determined by broth microdilution. Multilocus sequence types (MLSTs) and resistance mechanisms were determined using short- and long-read whole-genome sequencing (WGS). The impact of Pseudomonas-derived cephalosporinases (PDCs) on β-lactam resistance was demonstrated by cloning into an ampC-deficient PAO1 derivative (PAOΔC) and construction of 3D models. Genetic support of acquired β-lactamases was determined in silico from high-quality hybrid assemblies. In most cases, the isolates were recovered after treatment with ceftolozane-tazobactam or ceftazidime-avibactam. Seven isolates from different sequence types (STs) owed their β-lactam resistance to chromosomal mutations and all displayed specific substitutions in PDC: Phe121Leu and Gly222Ser, Pro154Leu, Ala201Thr, Gly214Arg, ΔGly203-Glu219, and Glu219Lys. In the other eight isolates, the ST175 clone was overrepresented (6 isolates) and associated with IMP-28 and IMP-13, whereas two ST1284 isolates produced VIM-2. The cloned PDCs conferred enhanced cephalosporin resistance. The 3D PDC models revealed rearrangements affecting residues involved in cephalosporin hydrolysis. Carbapenemases were chromosomal (VIM-2) or plasmid-borne (IMP-28, IMP-13) and associated with class-1 integrons located in Tn402-like transposition modules. Our findings highlighted that cephalosporin/β-lactamase inhibitors are potential selectors of MDR/XDR P. aeruginosa strains producing PDC variants or metallo-β-lactamases. Judicious use of these agents is encouraged., his work was supported by Projects and PI18/00501 to GB PI17/01482 and PI20/01212 awarded to AB, all within in the National Plan for Scientific Research, Development and Technological Innovation 2013 to 2016 and funded by the ISCIII – General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe”. The study was also funded by project IN607A 2020/05 (GAIN-Agencia Gallega de Innovación – Consellería de Economía, Emprego e Industria) awarded to GB and IN607D 2021/12 awarded to AB. This work was also supported by Planes Nacionales de I+D+i2008 to 2011/2013 to 2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectiosus Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth from 2014 to 2020. CGB acknowledges the financial support from the Spanish Ministry of Science and Innovation (PID2019-105512RB-I00), the Xunta de Galicia (ED431C 2021/29) and Centro singular de investigación de Galicia accreditation from 2019 to 2022 (ED431G 2019/03), and the European Regional Development Fund (ERDF). CLM was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and PGS was financially supported by IN607A 2020/05 Grant (Xunta de Galicia). JCVU was financially supported by the pFIS program (ISCIII, PI17/01482). M.O. was financially supported by the Juan Rodés program (ISCIII-SERGAS, JR18/00006). JAS was financially supported by the Rio Hortega program (ISCIII-SERGAS, CM19/00219).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Diagnostic tool for surveillance, detection and monitoring of the high-risk clone K. pneumoniae ST15

  • Gato, Eva
  • Rodiño-Janeiro, Bruno Kotska
  • Gude, María José
  • Fernández-Cuenca, Felipe
  • Pascual, Álvaro
  • Viña Fernández, Anabel María
  • Pérez Gómez, Astrid
  • Bou, Germán
[Abstract] Background: The global spread of Klebsiella pneumoniae ST15, causing multi-continental outbreaks, contributes to the movement of resistance genes between clones increasing the antimicrobial resistance crisis. The genomic traits providing it with the ability to outcompete other bacteria and cause epidemics remain unclear. Aim: To identify the specific genomic traits of K. pneumoniae ST15 to develop a diagnostic test. Methods: An outbreak caused by K. pneumoniae occurred in Hospital A Coruña, Spain. Antimicrobial susceptibility analysis and molecular typing (PGFE and MLST) were performed. One isolate of each sequence type was selected for whole-genome sequencing analysis. Comparative analysis of genomes was performed using RAST. BLASTn was used to evaluate the presence of the fhaC and kpiD genes. Two hundred and ninety-four K. pneumoniae from a Spanish nationwide collection were analysed by PCR. Findings: Genotyping showed that 87.5% of the isolates tested belonged to a clone with a unique PFGE pattern which corresponded to ST15. Comparative genomic analysis of the different STs enabled us to determine the specific genomic traits of K. pneumoniae ST15. Two adherence-related systems (Kpi and KpFhaB/FhaC) were specific markers of this clone. Multiplex-PCR analysis with kpiD and fhaC oligonucleotides revealed that K. pneumoniae ST15 is specifically detected with a sensitivity of 100% and a specificity of 97.76%. The PCR results showed 100% concordance with the MLST and whole-genome sequencing data. Conclusion: K. pneumoniae ST15 possesses specific genomic traits that could favour its dissemination. They could be used as targets to detect K. pneumoniae ST15 with high sensitivity and specificity., This work was supported by projects PI18/00501 (awarded to G.B.), p-01216A and IJCI-2016-29524 (awarded to A.P.), funded by the Instituto de Salud Carlos III, Spanish Society of Infectious Diseases and Clinical Microbiology and Spanish Ministry of Economy, Industry and Competitiveness (MEIC). A.P. and E.G. are supported by the Miguel Servet (CP22CIII-00007) and Sara Borrel programs, respectively, of the Instituto de Salud Carlos III, Spain., Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; p-01216A
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections

  • Arca-Suárez, Jorge
  • Lasarte-Monterrubio, Cristina
  • Rodiño-Janeiro, Bruno Kotska
  • Cabot, Gabriel
  • Vázquez-Ucha, Juan Carlos
  • Rodríguez-Iglesias, Manuel
  • Galán-Sánchez, Fátima
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Oliver, Antonio
  • Bou, Germán
[Abstract] Background: The development of resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of Pseudomonas aeruginosa infections is concerning. Objectives: Characterization of the mechanisms leading to the development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR P. aeruginosa infections. Methods: Four paired ceftolozane/tazobactam- and ceftazidime/avibactam-susceptible/resistant isolates were evaluated. MICs were determined by broth microdilution. STs, resistance mechanisms and genetic context of β-lactamases were determined by genotypic methods, including WGS. The OXA-10 variants were cloned in PAO1 to assess their impact on resistance. Models for the OXA-10 derivatives were constructed to evaluate the structural impact of the amino acid changes. Results: The same XDR ST253 P. aeruginosa clone was detected in all four cases evaluated. All initial isolates showed OprD deficiency, produced an OXA-10 enzyme and were susceptible to ceftazidime, ceftolozane/tazobactam, ceftazidime/avibactam and colistin. During treatment, the isolates developed resistance to all cephalosporins. Comparative genomic analysis revealed that the evolved resistant isolates had acquired mutations in the OXA-10 enzyme: OXA-14 (Gly157Asp), OXA-794 (Trp154Cys), OXA-795 (ΔPhe153-Trp154) and OXA-824 (Asn143Lys). PAO1 transformants producing the evolved OXA-10 derivatives showed enhanced ceftolozane/tazobactam and ceftazidime/avibactam resistance but decreased meropenem MICs in a PAO1 background. Imipenem/relebactam retained activity against all strains. Homology models revealed important changes in regions adjacent to the active site of the OXA-10 enzyme. The blaOXA-10 gene was plasmid borne and acquired due to transposition of Tn6746 in the pHUPM plasmid scaffold. Conclusions: Modification of OXA-10 is a mechanism involved in the in vivo acquisition of resistance to cephalosporin/β-lactamase inhibitor combinations in P. aeruginosa., This work was supported by MSD through the Investigator Initiated Studies Program, which provided financial support and relebactam. This work was also supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III (ISCIII), through grants PI15/00860 and PI18/00501 to G.B., PI18/00076 to A.O. and P14/00059 and P17/01482 to A.B. Support was also provided by: Planes Nacionales de I + D+i 2013-2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by the European Development Regional Fund ‘A way to achieve Europe’; and the operative Intelligent Growth Program 2014-2020. C.G.-B. acknowledges financial support from the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), the Xunta de Galicia [ED431B 2018/04 and Centro singular de investigación de Galicia accreditation 2019-2022 (ED431G 2019/03)] and the European Regional Development Fund (ERDF). J.A.-S. was financially supported by the Fundación Profesor Novoa Santos through a Post-Especialización Grant (2019) and by the Rio Hortega Program (ISCIII, CM19/00219). J.C.V.-U. was financially supported by the pFIS Program (ISCIII, PI17/01482). C.L.-M. was financially supported by an IN606A-2019/029 Grant (Xunta de Galicia).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification

  • Gato, Eva
  • Guijarro-Sánchez, Paula
  • Alonso-García, Isaac
  • Pedraza-Merino, Rosa
  • Conde, Adrián
  • Lence, Emilio
  • Rumbo-Feal, Soraya
  • Peña-Escolano, Andrea
  • Lasarte-Monterrubio, Cristina
  • Blanco Martín, Tania
  • Fernández González, Ana
  • Fernández-López, María del Carmen
  • Maceiras, Romina
  • Martínez Guitián, Marta
  • Vázquez-Ucha, Juan Carlos
  • Martínez-Martínez, Luis
  • González-Bello, Concepción
  • Arca-Suárez, Jorge
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] Objectives: In order to inform and anticipate potential strategies aimed at combating KPC-producing Klebsiella pneumoniae infections, we analysed imipenem/relebactam and ceftazidime/avibactam single-step mutant frequencies, resistance development trajectories, differentially selected resistance mechanisms and their associated fitness cost using four representative high-risk K. pneumoniae clones. Methods: Mutant frequencies and mutant preventive concentrations were determined using agar plates containing incremental concentrations of β-lactam/β-lactamase inhibitor. Resistance dynamics were determined through incubation for 7 days in 10 mL MH tubes containing incremental concentrations of each antibiotic combination up to their 64 × baseline MIC. Two colonies per strain from each experiment were characterized by antimicrobial susceptibility testing, whole genome sequencing and competitive growth assays (to determine in vitro fitness). KPC variants associated with imipenem/relebactam resistance were characterized by cloning and biochemical experiments, atomic models and molecular dynamics simulation studies. Results: Imipenem/relebactam prevented the emergence of single-step resistance mutants at lower concentrations than ceftazidime/avibactam. In three of the four strains evaluated, imipenem/relebactam resistance development emerged more rapidly, and in the ST512/KPC-3 clone reached higher levels compared to baseline MICs than for ceftazidime/avibactam. Lineages evolved in the presence of ceftazidime/avibactam showed KPC substitutions associated with high-level ceftazidime/avibactam resistance, increased imipenem/relebactam susceptibility and low fitness costs. Lineages that evolved in the presence of imipenem/relebactam showed OmpK36 disruption, KPC modifications (S106L, N132S, L167R) and strain-specific substitutions associated with imipenem/relebactam resistance and high fitness costs. Imipenem/relebactam-selected KPC derivatives demonstrated enhanced relebactam resistance through important changes affecting relebactam recognition and positioning. Conclusions: Our findings anticipate potential resistance mechanisms affecting imipenem/relebactam during treatment of KPC-producing K. pneumoniae infections., This work was supported by MSD through the Investigator Initiated Studies Program, which provided financial support (to G.B.) and relebactam. This work was also supported by the Fondo de Investigación Sanitaria (grant numbers PI17/01482 and PI20/01212 for A.B. and PI18/00501 and PI21/00704 for G.B.) integrated in the Plan Nacional de I1D and funded by the Instituto de Salud Carlos III (ISCIII), CIBERINFEC (CIBER de Enfermedades Infecciosas). The research was also funded by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0004 and no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research—European Regional Development Fund (FEDER) ‘A way of making Europe.’ The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12, A.B. and IN607A 2016/22, G.B.). PGS was financially supported by IN606A-2021/021. I.A.-G was financially supported by the Rio Hortega program (ISCIII, CM21/00076). J.C.V.-U. was financially supported by the ISCIII project FI18/00315. C.L.-M. was financially supported by IN606A-2019/ 029. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026). Financial support from the Spanish Agency of Research (PID2019-105512RB-I00/AEI/10.13039/501100011033, CG-B), the Xunta de Galicia [ED431C 2021/29 and the Centro singular de investigación de Galicia accreditation 2019–2022 (ED431G 2019/03), CG-B], and the European Regional Development Fund (ERDF) is gratefully acknowledged. AC acknowledges Banco Santander for his fellowship. We are also grateful to the Centro de Supercomputación de Galicia (CESGA) for use of the Finis Terrae computer., Xunta de Galicia; IN607D2021/12, Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; IN606A-2021/021, Xunta de Galicia; ED431C 2021/29, Xunta de Galicia; ED431G 2019/03
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Rapid detection of KPC-producing Enterobacterales by using a modified Carba NP test with imipenem/relebactam

  • Oviaño, Marina
  • de la Luna Ramírez, Cecilia
  • González-Bardanca, Mónica
  • Candela, Ana
  • Bou, Germán
Brief report, [Abstract] Introduction: Here, we propose a novel modified Carba NP test for detecting KPC-producing Enterobacterales using imipenem/relebactam. Material and methods: The test performance was evaluated in a random selection of 160 previously molecularly characterized clinical isolates carrying the 110 blaKPC, 1 blaGES, 12 blaVIM, 4 blaIMP, 3 blaNDM and 42 blaOXA-48-like genes. The proposed method relies on the detection of imipenem hydrolysis in an imipenem/relebactam antibiotic solution and subsequent visual interpretation by color change. Results: All class A producing Enterobacterales (111/111) were detected using imipenem/relebactam as no visual appreciation of color change was perceived due to a nule hydrolysis of imipenem in the antibiotic solution. Overall, the assay showed 100% sensitivity (111/111) and specificity (69/69) for detecting class A KPC-producing Enterobacterales. Discussion: The biochemical assay provides very reliable results for detecting KPC-producing Enterobacterales, with a turnaround time of less than 1 hour, minimum handling and no specialized equipment required., [Resumen] Introducción. En este manuscrito proponemos un novedoso ensayo basado en el Carba NP test para la detección de Enterobacterales productoras de KPC utilizando imipenem/relebactam. Material y métodos. La evaluación se realizó en una selección aleatoria de 160 aislados clínicos previamente caracterizados molecularmente que portaban los genes 110 blaKPC, 1 blaGES, 12 blaVIM, 4 blaIMP, 3 blaNDM y 42 blaOXA-48-like. El método propuesto se basa en la detección de la hidrólisis de imipenem en una solución de imipenem/relebactam y posteriormente su interpretación mediante un cambio de color. Resultados. El ensayo tiene una sensibilidad (111/111) y una especificidad (69/69) del 100% para detectar Enterobacterales productoras de KPC, de clase A. Discusión. Este ensayo bioquímico proporciona resultados muy fiables para la detección de Enterobacterales productoras de KPC, con un tiempo de respuesta inferior a 1 h, además de una manipulación mínima y sin necesidad de ningún equipamiento especializado., The results of this work have been funded by the Projects N° PI15/00860 and PI18/00501, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research – European Regional Development Fund (FEDER) “A way of making Europe”.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Emergence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacterales in Spain studied by whole-genome sequencing

  • Arca-Suárez, Jorge
  • Rodiño-Janeiro, Bruno Kotska
  • Pérez Gómez, Astrid
  • Guijarro-Sánchez, Paula
  • Vázquez-Ucha, Juan Carlos
  • Cruz, Fernando
  • Gómez-Garrido, Jéssica
  • Alioto, Tyler S.
  • Álvarez-Tejado, Miguel
  • Gut, Marta
  • Gut, Ivo
  • Oviaño, Marina
  • Beceiro Casas, Alejandro
  • Bou, Germán
Comparative study, [Abstract] The emergence of 16S rRNA methyltransferases (RMTs) in Gram-negative pathogens bearing other clinically relevant resistance mechanisms, such as carbapenemase-producing Enterobacterales (CPE), is becoming an alarming concern. We investigated the prevalence, antimicrobial susceptibility, resistance mechanisms, molecular epidemiology and genetic support of RMTs in CPE isolates from Spain. This study included a collection of 468 CPE isolates recovered during 2018 from 32 participating Spanish hospitals. MICs were determined using the broth microdilution method, the agar dilution method (fosfomycin) or MIC gradient strips (plazomicin). All isolates were subjected to hybrid whole-genome sequencing (WGS). Sequence types (STs), core genome phylogenetic relatedness, horizontally acquired resistance mechanisms, plasmid analysis and the genetic environment of RMTs were determined in silico from WGS data in all RMT-positive isolates. Among the 468 CPE isolates evaluated, 24 isolates (5.1%) recovered from nine different hospitals spanning five Spanish regions showed resistance to all aminoglycosides and were positive for an RMT (21 RmtF, 2 ArmA and 1 RmtC). All RMT-producers showed high-level resistance to all aminoglycosides, including plazomicin, and in most cases exhibited an extensively drug-resistant susceptibility profile. The RMT-positive isolates showed low genetic diversity and were global clones of Klebsiella pneumoniae (ST147, ST101, ST395) and Enterobacter cloacae (ST93) bearing blaOXA-48, blaNDM-1 or blaVIM-1 carbapenemase genes. RMTs were harboured in five different multidrug resistance plasmids and linked to efficient mobile genetic elements. Our findings highlight that RMTs are emerging among clinical CPE isolates from Spain and their spread should be monitored to preserve the future clinical utility of aminoglycosides and plazomicin., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI15/00860 and PI18/00501 to GB and P17/01482 to AB. MG and IG acknowledge the support of the MEIC through the Instituto de Salud Carlos III and the 2014–2020 Smart Growth Operating Program, to the EMBL partnership and co-financing with the European Regional Development Fund [MINECO/FEDER, BIO2015-71792-P]. MG and IG also acknowledge the support of the Centro de Excelencia Severo Ochoa, and the Generalitat de Catalunya through the Departament de Salut, Departament d'Empresa i Coneixement and the CERCA Programme. Support was also provided by Planes Nacionales de I+D+i 2013–2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases [REIPI RD16/0016/006] co-financed by the European Regional Development Fund ‘A Way to Achieve Europe’, and the operative Intelligent Growth program 2014–2020. JAS was financially supported by the Fundacion Profesor Novoa Santos through a Post-especialización grant and by the Rio Hortega program [ISCIII-SERGAS, CM19/00219]. MO was financially supported by the Juan Rodés program [ISCIII-SERGAS, JR18/00006]. JCVU was financially supported by the pFIS program [ISCIII, PI17/01482].
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection

  • Arca-Suárez, Jorge
  • Vázquez-Ucha, Juan Carlos
  • Fraile-Ribot, Pablo Arturo
  • Lence, Emilio
  • Cabot, Gabriel
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Rodríguez-Iglesias, Manuel
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Galán-Sánchez, Fátima
  • Oliver, Antonio
  • Bou, Germán
[Abstract] Background: Pseudomonas aeruginosa may develop resistance to novel cephalosporin/β-lactamase inhibitor combinations during therapy through the acquisition of structural mutations in AmpC. Objectives: To describe the molecular and biochemical mechanisms involved in the development of resistance to ceftolozane/tazobactam in vivo through the selection and overproduction of a novel AmpC variant, designated PDC-315. Methods: Paired susceptible/resistant isolates obtained before and during ceftolozane/tazobactam treatment were evaluated. MICs were determined by broth microdilution. Mutational changes were investigated through WGS. Characterization of the novel PDC-315 variant was performed through genotypic and biochemical studies. The effects at the molecular level of the Asp245Asn change were analysed by molecular dynamics simulations using Amber. Results: WGS identified mutations leading to modification (Asp245Asn) and overproduction of AmpC. Susceptibility testing revealed that PAOΔC producing PDC-315 displayed increased MICs of ceftolozane/tazobactam, decreased MICs of piperacillin/tazobactam and imipenem and similar susceptibility to ceftazidime/avibactam compared with WT PDCs. The catalytic efficiency of PDC-315 for ceftolozane was 10-fold higher in relation to the WT PDCs, but 3.5- and 5-fold lower for piperacillin and imipenem. IC50 values indicated strong inhibition of PDC-315 by avibactam, but resistance to cloxacillin inhibition. Analysis at the atomic level explained that the particular behaviour of PDC-315 is linked to conformational changes in the H10 helix that favour the approximation of key catalytic residues to the active site. Conclusions: We deciphered the precise mechanisms that led to the in vivo emergence of resistance to ceftolozane/tazobactam in P. aeruginosa through the selection of the novel PDC-315 enzyme. The characterization of this new variant expands our knowledge about AmpC-mediated resistance to cephalosporin/β-lactamase inhibitors in P. aeruginosa., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI15/00860 and PI18/00501 to G.B., PI18/00076 to A.O., and P14/00059 and P17/01482 to A.B. Support was also provided by Planes Nacionales de I + D+i 2013–2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by the European Development Regional Fund ‘A way to achieve Europe’; and the operative Intelligent Growth program 2014–2020. C.G-B. acknowledges financial support from the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R, C.G-B.), the Xunta de Galicia [ED431B 2018/04 and Centro singular de investigación de Galicia accreditation 2019-2022 (ED431G 2019/03)], and the European Regional Development Fund (ERDF). E.L. thanks the Xunta de Galicia for his postdoctoral fellowship. J.A-S. was financially supported by the Fundación Profesor Novoa Santos through a Post-especialización Grant (2019) and by the Rio Hortega program (ISCIII, CM19/00219). J.C.V-U. was financially supported by the pFIS program (ISCIII, PI17/01482). M.M-G. was financially supported by a Clara Roy grant (SEIMC) and C.L-M. by IN606A-2019/029.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Live Auxotrophic Vaccines Contribute to Protection Against Chronic Lung Infections Caused by Pseudomonas Aeruginosa in C57BL/6 Mice

  • Fuentes-Valverde, Víctor
  • Correia, Alexandra
  • García, Patricia
  • Pérez-Antón, Elena
  • Amorim, Irina
  • Rumbo-Feal, Soraya
  • Cabral, M. P.
  • Vilanova, Manuel
  • Moscoso, Miriam
  • Bou, Germán
[Abstract] Pseudomonas aeruginosa causes severe, often multidrug-resistant lung infections, especially in individuals with cystic fibrosis, highlighting vaccination as a promising preventive approach. This study evaluated intranasal and intradermal immunization with a D-glutamate auxotrophic P. aeruginosa strain (PAO1 ΔmurI) and two of its derivatives, one with additional D-alanine auxotrophy and another exhibiting reduced lipopolysaccharide-associated toxicity, in C57BL/6 mice using both acute and chronic lung infection models. Mice received two or three doses at various intervals, and safety was assessed through clinical and weight monitoring. A high-dose, 2-administration intranasal regimen protected against acute infection but induced transient weight loss, while a lower-dose, 3-administration regimen minimized toxicity. Immunized mice exhibited robust IL-17A production and increased IFN-γ responses. Following challenge with mucoid strains, vaccinated mice showed reduced lung bacterial loads, suggesting a partial protection against chronic infection. These findings support the potential of auxotrophic live vaccines to mitigate disease severity in patients with cystic fibrosis., This work was supported by a grant from the SERGAS-Galician Healthcare Service (Program “Innova Saúde”), CIBERINFEC, La Caixa Foundation -Caixa Capital Risc (CI16-00057), and the projects PI18/00501 and PI21/00704 to GB, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 from the Ministry of Economy and Competitiveness and the Institute of Health Carlos III. VF-V was supported by a predoctoral fellowship from the Conselleria de Cultura, Xunta de Galicia (IN606A-2019/012).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain

  • Vázquez-Ucha, Juan Carlos
  • Alonso-García, Isaac
  • Guijarro-Sánchez, Paula
  • Lasarte-Monterrubio, Cristina
  • Álvarez-Fraga, Laura
  • Cendón-Esteve, Arnau
  • Outeda, Michelle
  • Maceiras, Romina
  • Peña-Escolano, Andrea
  • Martínez Guitián, Marta
  • Arca-Suárez, Jorge
  • Bou, Germán
  • Beceiro Casas, Alejandro
Multicenter study, [Abstract] Metallo-β-lactamase (MBL)-producing Enterobacterales are of particular concern because they are widely disseminated and difficult to treat, being resistant to almost all β-lactam antibiotics. Aztreonam is not hydrolysed by MBLs but is labile to serine β-lactamases (SBLs), which are usually co-produced by MBL-producing Enterobacterales. This study investigated the activity of aztreonam in combination with novel β-lactamase inhibitors (BLIs) against a national multi-centre study collection of strains co-producing MBLs and SBLs. Fifty-five clinical isolates co-producing MBLs (41 VIM producers, 10 NDM producers and 4 IMP producers) and SBLs were selected, and whole-genome sequencing (WGS) was performed. The minimum inhibitory concentration (MIC) values of aztreonam, aztreonam/avibactam, aztreonam/relebactam, aztreonam/zidebactam, aztreonam/taniborbactam, aztreonam/vaborbactam and aztreonam/enmetazobactam were determined. β-lactam/BLI resistance mechanisms were analysed by WGS. All BLIs decreased the MIC values of aztreonam for strains that were not susceptible to aztreonam. Aztreonam/zidebactam (MIC ≤1 mg/L for 96.4% of isolates), aztreonam/avibactam (MIC ≤1 mg/L for 92.7% of isolates) and aztreonam/taniborbactam (MIC ≤1 mg/L for 87.3 % of isolates) were the most active combinations. For other aztreonam/BLI combinations, 50-70% of the isolates yielded MIC values ≤1 mg/L. WGS data revealed that mutations in PBP3, defective OmpE35/OmpK35 porins, and the presence of extended-spectrum β-lactamases and class C β-lactamases were some of the resistance mechanisms involved in reduced susceptibility to aztreonam/BLIs. Combinations of aztreonam with new BLIs show promising activity against Enterobacterales co-producing MBLs and SBLs, particularly aztreonam/zidebactam, aztreonam/avibactam and aztreonam/taniborbactam. The present results show that these novel drugs may represent innovative therapeutic strategies by their use in yet-unexplored combinations as solutions for difficult-to-treat infections., This study was funded by Instituto de Salud Carlos III (ISCIII) through Projects N° Exp PI20/01212 and PI18/00501, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2017-2020, and co-funded by European Union – European Regional Development Fund ‘A way to make Europe’. The work was also supported by CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB21/13/00055), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – NextGenerationEU. In addition, the study was funded by Project IN607A 2020/05 (Agencia Gallega de Innovación – Consellería de Economía, Emprego e Industria) awarded to GB, and Project IN607D 2021/12 awarded to AB. The work was also supported by Planes Nacionales de I+D+i 2017-2020 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006), co-financed by European Development Regional Fund ‘A way to achieve Europe’ and operative programme Intelligent Growth 2014-2020. JA-S was financially supported by the Juan Rodés programme (ISCIII, JR21/00026), JCV-U was financially supported by IN606B-2022/009 (Xunta de Galicia), CL-M was financially supported by IN606A-2019/029 (Xunta de Galicia) and PI20/01212 (ISCIII), and PG-S was financially supported by IN606A 2021/021 (Xunta de Galicia). AC and MO were financially supported by IN607D 2021/12. IA-G was financially supported by the Río Hortega programme (ISCIII, CM21/00076). LA-F was financially supported by IN606B- 2018/011 (Xunta de Galicia). MM-G was financially supported by RSU.UDC.M505 (Ministerio de Universidades)., Xunta de Galicia; IN606B-2022/009, Xunta de Galicia; IN606A-2019/029, Xunta de Galicia; IN606A 2021/021, Xunta de Galicia; IN606B- 2018/011, Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Challenging antimicrobial susceptibility and evolution of resistance (oxa-681) during treatment of a long-term nosocomial infection caused by a pseudomonas aeruginosa ST175 Clone

  • Arca-Suárez, Jorge
  • Fraile-Ribot, Pablo Arturo
  • Vázquez-Ucha, Juan Carlos
  • Cabot, Gabriel
  • Martínez Guitián, Marta
  • Lence, Emilio
  • González-Bello, Concepción
  • Beceiro Casas, Alejandro
  • Rodríguez-Iglesias, Manuel
  • Galán, Fátima
  • Bou, Germán
  • Oliver, Antonio
Case report, [Abstract] Selection of extended-spectrum mutations in narrow-spectrum oxacillinases (e.g., OXA-2 and OXA-10) is an emerging mechanism for development of in vivo resistance to ceftolozane-tazobactam and ceftazidime-avibactam in Pseudomonas aeruginosa Detection of these challenging enzymes therefore seems essential to prevent clinical failure, but the complex phenotypic plasticity exhibited by this species may often lead to their underestimation. The underlying resistance mechanisms of two sequence type 175 (ST175) P. aeruginosa isolates showing multidrug-resistant phenotypes and recovered at early and late stages of a long-term nosocomial infection were evaluated. Whole-genome sequencing (WGS) was used to investigate resistance genomics, whereas molecular and biochemical methods were used for characterization of a novel extended-spectrum OXA-2 variant selected during therapy. The metallo-β-lactamase blaVIM-20 and the narrow-spectrum oxacillinase blaOXA-2 were present in both isolates, although they differed by an inactivating mutation in the mexB subunit, present only in the early isolate, and in a mutation in the blaOXA-2 β-lactamase, present only in the final isolate. The new OXA-2 variant, designated OXA-681, conferred elevated MICs of the novel cephalosporin-β-lactamase inhibitor combinations in a PAO1 background. Compared to OXA-2, kinetic parameters of the OXA-681 enzyme revealed a substantial increase in the hydrolysis of cephalosporins, including ceftolozane. We describe the emergence of the novel variant OXA-681 during treatment of a nosocomial infection caused by a Pseudomonas aeruginosa ST175 high-risk clone. The ability of OXA-681 to confer cross-resistance to ceftolozane-tazobactam and ceftazidime-avibactam together with the complex antimicrobial resistance profiles exhibited by the clinical strains harboring this new enzyme argue for maintaining active surveillance on emerging broad-spectrum resistance in P. aeruginosa., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI1800076 to A.O., PI15/00860 and PI18/00501 to G.B., and P14/00059 and P17/01482 to A.B. and through grants from the Spanish Ministry of Economy and Competitiveness (SAF2016-75638-R) and the Xunta de Galicia (ED431G/09) to C.G.-B. This work was also supported by the European Regional Development Fund A Way To Achieve Europe ERDF, through the Spanish Network for Research in Infectious Diseases (RD16/0016). J.C.V.-U. was financially supported by the pFIS program (ISCIII, PI17/01482), and M.M.-G. was financially supported by a Clara Roy grant (SEIMC).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections

  • Alonso-García, Isaac
  • Vázquez-Ucha, Juan Carlos
  • Lasarte-Monterrubio, Cristina
  • González-Mayo, Elena
  • Lada-Salvador, Paula
  • Vela-Fernández, Ramón
  • Aja-Macaya, Pablo
  • Guijarro-Sánchez, Paula
  • Rumbo-Feal, Soraya
  • Muíño-Andrade, María José
  • Fernández González, Ana
  • Martínez Guitián, Marta
  • Beceiro Casas, Alejandro
  • Rodríguez-Iglesias, Manuel
  • Oliver, Antonio
  • Arca-Suárez, Jorge
  • Galán-Sánchez, Fátima
  • Bou, Germán
[Abstract] Objectives: To describe and characterize the emergence of resistance to ceftolozane/tazobactam, ceftazidime/avibactam and imipenem/relebactam in a patient receiving ceftazidime/avibactam treatment for an MDR Pseudomonas aeruginosa CNS infection. Methods: One baseline (PA1) and two post-exposure (PA2 and PA3) isolates obtained before and during treatment of a nosocomial P. aeruginosa meningoventriculitis were evaluated. MICs were determined by broth microdilution. Mutational changes were investigated through WGS. The impact on β-lactam resistance of mutations in blaPDC and mexR was determined through cloning experiments and complementation assays. Results: Isolate PA1 showed baseline resistance mutations in DacB (I354A) and OprD (N142fs) conferring resistance to conventional antipseudomonals but susceptibility to ceftazidime/avibactam, ceftolozane/tazobactam and imipenem/relebactam. Post-exposure isolates showed two divergent ceftazidime/avibactam-resistant phenotypes associated with distinctive mutations affecting the intrinsic P PDC β-lactamase (S254Ins) (PA2: ceftolozane/tazobactam and ceftazidime/avibactam-resistant) or MexAB-OprM negative regulator MexR in combination with modification of PBP3 (PA3: ceftazidime/avibactam and imipenem/relebactam-relebactam-resistant). Cloning experiments demonstrated the role of PDC modification in resistance to ceftolozane/tazobactam and ceftazidime/avibactam. Complementation with a functional copy of the mexR gene in isolate PA3 restored imipenem/relebactam susceptibility. Conclusions: We demonstrated how P. aeruginosa may simultaneously develop resistance and compromise the activity of new β-lactam/β-lactamase inhibitor combinations when exposed to ceftazidime/avibactam through selection of mutations leading to PDC modification and up-regulation of MexAB-OprM-mediated efflux., This work was supported by the Fondo de Investigación Sanitaria (grant numbers PI22/01212 for J.A.-S., PI17/01482 and PI20/01212 for A.B., PI21/00017 for A.O., and PI18/00501 and PI21/00704 for G.B. integrated in the Plan Nacional de I1D and funded by the Instituto de Salud Carlos III, ISCIII). This research was also funded by CIBERINFEC, no. CB21/13/00055 and no. CB21/13/00099 (CIBER de Enfermedades Infecciosas), and by the Spanish Network of Research in Infectious Diseases (REIPI), no. RD16/0016/0004 and no. RD16/0016/0006, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research–European Regional Development Fund (FEDER) ‘A way of making Europe’. The study was also funded by GAIN (Agencia Gallega de Innovacion, Conselleria de Economia, Emprego e Industria; IN607D2021/12 to A.B. and IN607A 2016/22 to G.B.). I.A.-G was financially supported by the Rio Hortega programme (ISCIII, CM21/00076). J.C.V.-U. was financially supported by the ISCIII project FI18/00315. C.L.-M. was financially supported by IN606A-2019/029. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026)., Xunta de Galicia; IN607D2021/12, Xunta de Galicia; IN607A 2016/22
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Syzygium aromaticum (clove) and Thymus zygis (thyme) essential oils increase susceptibility to colistin in the nosocomial pathogens Acinetobacter baumannii and Klebsiella pneumoniae

  • Poza, Margarita
  • Vázquez-Ucha, Juan Carlos
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Conde-Pérez, Kelly
  • Arca-Suárez, Jorge
  • Álvarez-Fraga, Laura
  • Pérez Gómez, Astrid
  • Crecente-Campo, José
  • Alonso, María J.
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] The discovery of new antibiotics that are effective against Acinetobacter baumannii and Enterobacteralesis a research priority. Several essential oils (EOs) have displayed some antimicrobial activity and could potentially act as antibiotic adjuvants. Research in this area aims to develop new therapeutic alternatives to treat infections caused by these pathogens. MICs of different EOs were determined against A. baumannii and Klebsiella pneumoniae. Combined disk diffusion tests and checkerboard assays were used to study the synergy between the EOs and antibiotics. The fractional inhibitory concentration index (FICindex) was calculated in order to categorize the interaction. Time-kill assays were also performed. The EOs that displayed the highest levels of antimicrobial activity were clove (Syzygium aromaticum L.) and thyme (Thymus zygis L.). Combined disk diffusion tests and checkerboard assays revealed synergy between these EOs and colistin. Addition of either clove or thyme EO decreased the MIC of colistin by 8- to 64-fold and 8- to 128-fold in the colistin-resistant A. baumannii and K. pneumoniae strains, respectively (FICindex ≤ 0.5, synergy). MICs were also reduced in the colistin-susceptible strains. Time-kill assays also indicated the strong activity of the combined therapy. In summary, the use of clove or thyme EO in combination with colistin could improve the efficacy of the antibiotic and significantly reduce the concentrations needed to inhibit growth of A. baumannii and K. pneumoniae., Funding: This study was funded by projects IN607A 2016/22 (GAIN), PI15/00860, PI18/00501 and REIPI RD16/0016/006 (co-financed by the European Development Regional Fund "A way to achieve Europe" and the operative Intelligent Growth program 2014-2020) awarded to GB, PI14/00059 and PI17/01482 awarded to AB and MP (Instituto de Salud Carlos III). JCVU was financially supported the pFIS Programme (FI18/00315, ISCIII), MMG by a Clara Roy grant (SEIMC), KCP by IN607A 2016/22 (GAIN), CLM by IN606A-2019/029 (GAIN) and JAS by the Rio Hortega program (CM19/00219, ISCIII) and the FPNS (post-specialization grant). Acknowledgements: We thank Dr J.D. Boyce for the kind gift of ATCC19606ΔlpxC. We also thank Dr S. Pournaras for the kind gift of AB248 and AB249.
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Engineering and evaluation of a live-attenuated vaccine candidate with enhanced Type 1 fimbriae expression to optimize protection against Salmonella Typhimurium

  • García, Patricia
  • Rodríguez-Coello, Arianna
  • García-Pose, Andrea
  • Fernández-López, María del Carmen
  • Muras, Andrea
  • Moscoso, Miriam
  • Beceiro Casas, Alejandro
  • Bou, Germán
[Abstract] Background:Salmonella Typhimurium is a major zoonotic pathogen, in which type 1 fimbriae play a crucial role in intestinal colonization and immune modulation. This study aimed to improve the protective immunity of a previously developed growth-deficient strain-a double auxotroph for D-glutamate and D-alanine-by engineering the inducible expression of type 1 fimbriae. Methods: PtetA-driven expression of the fim operon was achieved by λ-Red mutagenesis. fimA expression was quantified by qRT-PCR, and fimbriation visualized by transmission electron microscopy. Adhesive properties were evaluated through FimH sequence analysis, yeast agglutination, mannose-binding/inhibition assays, and HT-29 cell adherence. BALB/c mice were immunized orogastrically with IRTA ΔΔΔ or IRTA ΔΔΔ PtetA::fim. Safety and immunogenicity were assessed by clinical monitoring, bacterial load, fecal shedding, ELISA tests, and adhesion/blocking assays using fecal extracts. Protection was evaluated after challenging with wild-type and heterologous strains. Results: IRTA ΔΔΔ PtetA::fim showed robust fimA expression, dense fimbrial coverage, a marked mannose-sensitive adhesive phenotype and enhanced HT-29 attachment. Fimbrial overexpression did not alter intestinal colonization or translocation to mesenteric lymph nodes (mLNs). Immunization elicited a mixed IgG1/IgG2a, significantly increased IgA and IgG against type 1 fimbriae-expressing Salmonella, and enhanced the ability of fecal extracts to inhibit the adherence of wild-type strains. Upon challenge (IRTA wild-type/20220258), IRTA ΔΔΔ PtetA::fim reduced infection burden in the cecum (-1.46/1.47-log), large intestine (-1.35/2.17-log), mLNs (-1.32/0.98-log) and systemic organs more effectively than IRTA ΔΔΔ. Conclusions: Inducible expression of type 1 fimbriae enhances mucosal immunity and protection, supporting their inclusion in next-generation Salmonella vaccines. Future work should assess cross-protection and optimize FimH-mediated targeting for mucosal delivery., This study was supported by a grant from SERGAS (The Galician Healthcare Service) (Programs “InnovaSaude” and “InnovaMicrolab”), the Spanish Network for Research in Infectious Diseases (RD16/0016/0006), CIBER-Consorcio Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (CB21/13/00055), project PI18/00501, funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (ERDF/ESF, “A way to make Europe”/”Investing in your future”) and PI21/00704, funded by ISCIII and co-funded by the European Union, awarded to GB. This research was also supported by Projects PI20/01212 and PI23/00851 awarded to A.B., funded by ISCIII and co-funded by the European Union, and by project IN607D 2021/12 awarded to A.B., funded by GAIN-Agencia Gallega de Innovación, Consellería de Economía, Emprego e Industria. A.R was supported by a predoctoral fellowship from the Instituto de Salud Carlos III (FI24/00178). A.M. was supported by a postdoctoral fellowship from the Instituto de Salud Carlos III (CD23/00057).
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Antimicrobial activity of Cefiderocol against the Carbapenemase-producing Enterobacter cloacae complex and characterization of reduced susceptibility associated with Metallo-β-Lactamase VIM-1

  • Lasarte-Monterrubio, Cristina
  • Guijarro-Sánchez, Paula
  • Vázquez-Ucha, Juan Carlos
  • Alonso-García, Isaac
  • Álvarez-Fraga, Laura
  • Outeda-García, Michelle
  • Martínez Guitián, Marta
  • Peña-Escolano, Andrea
  • Maceira, Romina
  • Lence, Emilio
  • González-Bello, Concepción
  • Arca-Suárez, Jorge
  • Bou, Germán
  • Beceiro Casas, Alejandro
[Abstract] Emergence of cefiderocol resistance among carbapenemase-producing Enterobacterales, particularly those in the Enterobacter cloacae complex (ECC), is becoming of alarming concern; however, the mechanistic basis of this phenomenon remains poorly understood. We describe the acquisition of VIM-1-mediated reduced cefiderocol susceptibility (MICs 0.5 to 4 mg/L) in a collection of 54 carbapenemase-producing isolates belonging to the ECC. MICs were determined by reference methodologies. Antimicrobial resistance genomic analysis was performed through hybrid WGS. The impact of VIM-1 production on cefiderocol resistance in the ECC background was examined at microbiological, molecular, biochemical, and atomic levels. Antimicrobial susceptibility testing yielded 83.3% susceptible isolates and MIC50/90 values of 1/4 mg/L. Decreased susceptibility to cefiderocol was mainly associated with isolates producing VIM-1, with cefiderocol MICs 2- to 4-fold higher than for isolates carrying other types of carbapenemases. E. cloacae and Escherichia coli VIM-1 transformants displayed significantly enhanced cefiderocol MICs. Biochemical assays with purified VIM-1 protein revealed low but detectable cefiderocol hydrolysis. Simulation studies revealed how cefiderocol is anchored to the VIM-1 active site. Additional molecular assays and WGS data analysis highlighted the implication of SHV-12 coproduction and suggested the inactivation of the FcuA-like siderophore receptor as further contributors to the higher cefiderocol MICs. Our findings warn of the potential of the VIM-1 carbapenemase to at least partly limit the activity of cefiderocol in the ECC. This effect is probably enhanced due to combination with additional mechanisms, such as ESBL production and siderophore inactivation, and indicates the need for active surveillance to extend the life span of this promising cephalosporin., This research was supported by Projects PI17/01482 and PI20/01212 awarded to AB, PI22/01212 to JAS and PI18/00501 to GB, within in the National Plan for Scientific Research, Development and Technological Innovation 2017 to 2020 and funded by the ISCIII-General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe.” The work was also supported by CIBERINFEC (CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III). The study was also funded by project IN607A 2020/05 (GAIN-Agencia Gallega de Innovación-Consellería de Economía, Emprego e Industria) awarded to GB and project IN607D 2021/12 awarded to AB. It was also supported by Planes Nacionales de I+D+i2017 to 2020 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth2014 to 2020. J.A.-S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026), J.C.V.-U. was financially supported by IN606B-2022/009 Grant (Xunta de Galicia), C.L.-M. was financially supported by IN606A-2019/029 Grant (Xunta de Galicia) and PGS was financially supported by IN606A 2021/021 Grant (Xunta de Galicia). M.O. was financially supported by IN607D 2021/12 (Xunta de Galicia). I.A.-G. was financially supported by the Rio Hortega program (ISCIII, CM21/00076). C.G.-B. acknowledges financial support from the Spanish Ministry of Science and Innovation (PID2019-105512RB-I00), the Xunta de Galicia (ED431C 2021/29 and the Centro singular de investigación de Galicia accreditation2019 to 2022 [ED431G 2019/03]), and the European Regional Development Fund (ERDF)., Xunta de Galicia; IN607A 2020/05, Xunta de Galicia; IN607D 2021/12, Xunta de Galicia; IN606B-2022/009, Xunta de Galicia; IN606A-2019/029, Xunta de Galicia; IN606A 2021/021, Xunta de Galicia; ED431C 2021/29, Xunta de Galicia; ED431G 2019/03
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Marine Organisms from the Yucatan Peninsula (Mexico) as a Potential Natural Source of Antibacterial Compounds

  • Pech-Puch, Dawrin
  • Pérez Povedano, Mar Anabel
  • Gómez, Patricia
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Vázquez-Ucha, Juan Carlos
  • Novoa Olmedo, María Lourdes
  • Guillén-Hernández, Sergio
  • Villegas-Hernández, Harold
  • Bou, Germán
  • Rodríguez, Jaime
  • Beceiro Casas, Alejandro
  • Jiménez, Carlos
[Abstract] A total of 51 sponges (Porifera) and 13 ascidians (Chordata) were collected on the coast of the Yucatan Peninsula (Mexico) and extracted with organic solvents. The resulting extracts were screened for antibacterial activity against four multidrug-resistant (MDR) bacterial pathogens: the Gram-negative Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa and the Gram-positive Staphylococcus aureus. The minimum inhibitory concentrations (MICs) of the organic extracts of each marine organism were determined using a broth microdilution assay. Extracts of eight of the species, in particular the Agelas citrina and Haliclona (Rhizoniera) curacaoensis, displayed activity against some of the pathogens tested. Some of the extracts showed similar MIC values to known antibiotics such as penicillins and aminoglycosides. This study is the first to carry out antimicrobial screening of extracts of marine sponges and ascidians collected from the Yucatan Peninsula. Bioassay-guided fractionation of the active extracts from the sponges Amphimedon compressa and A. citrina displayed, as a preliminary result, that an inseparable mixture of halitoxins and amphitoxins and (-)-agelasine B, respectively, are the major compounds responsible for their corresponding antibacterial activities. This is the first report of the antimicrobial activity of halitoxins and amphitoxins against major multidrug-resistant human pathogens. The promising antibacterial activities detected in this study indicate the coast of Yucatan Peninsula as a potential source of a great variety of marine organisms worthy of further research., This work was supported by Grants RTI2018-093634-B-C22 (AEI/FEDER, EU) from the State Agency for Research (AEI) of Spain, co-funded by the FEDER Programme from the European Union, by projects PI15/00860 and PI18/00501 to GB and PI14/00059 and PI17/01482 to AB (Instituto de Salud Carlos III) and BLUEBIOLAB (0474_BLUEBIOLAB_1_E), Programme INTERREG V A of Spain-Portugal (POCTEP). The study was also funded by projects IN607A 2016/22 (GAIN- Agencia Gallega de Innovación - Consellería de Economía, Emprego e Industria) and GRC2018/039 and Agrupación Estratégica CICA-INIBIC ED431E 2018/03 (Consellería de Educación, Universidades e Formación Profesional) from the Xunta de Galicia (autonomous government of the region). Support was also provided by Planes Nacionales de I+D+i 2013-2016 and ISCIII, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by European Development Regional Fund "A way to achieve Europe" and the operative program Intelligent Growth 2014-2020. J.C.V.U. was financially supported by the pFIS Programme (FI18/00315), M.M.G. was financially supported by a Clara Roy grant (SEIMC) and C.L.M. by IN606A-2019/029. D.P.P. received a fellowship from the program National Council of Science and Technology (CONACYT) of Mexico and the Secretariat of Research, Innovation and Higher Education (SIIES) of Yucatan (Mexico), Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; GRC2018/039, Xunta de Galicia; ED431E 2018/03, Xunta de Galicia; IN606A-2019/029
RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

Kpi, a Chaperone-Usher Pili System Associated with the Worldwide-Disseminated High-Risk Clone Klebsiella Pneumoniae ST-15

  • Gato, Eva
  • Vázquez-Ucha, Juan Carlos
  • Rumbo-Feal, Soraya
  • Álvarez-Fraga, Laura
  • Vallejo, J. A.
  • Martínez Guitián, Marta
  • Beceiro Casas, Alejandro
  • Ramos Vivas, Jose
  • Sola-Campoy, Pedro Juan
  • Pérez-Vázquez, María
  • Oteo, Jesús
  • Rodiño-Janeiro, Bruno Kotska
  • Romero, A.
  • Poza, Margarita
  • Bou, Germán
  • Pérez Gómez, Astrid
[Abstract] Control of infections caused by carbapenem-resistant Klebsiella pneumoniae continues to be challenging. The success of this pathogen is favored by its ability to acquire antimicrobial resistance and to spread and persist in both the environment and in humans. The emergence of clinically important clones, such as sequence types 11, 15, 101, and 258, has been reported worldwide. However, the mechanisms promoting the dissemination of such high-risk clones are unknown. Unraveling the factors that play a role in the pathobiology and epidemicity of K. pneumoniae is therefore important for managing infections. To address this issue, we studied a carbapenem-resistant ST-15 K. pneumoniae isolate (Kp3380) that displayed a remarkable adherent phenotype with abundant pilus-like structures. Genome sequencing enabled us to identify a chaperone-usher pili system (Kpi) in Kp3380. Analysis of a large K. pneumoniae population from 32 European countries showed that the Kpi system is associated with the ST-15 clone. Phylogenetic analysis of the operon revealed that Kpi belongs to the little-characterized γ2-fimbrial clade. We demonstrate that Kpi contributes positively to the ability of K. pneumoniae to form biofilms and adhere to different host tissues. Moreover, the in vivo intestinal colonizing capacity of the Kpi-defective mutant was significantly reduced, as was its ability to infect Galleria mellonella. The findings provide information about the pathobiology and epidemicity of Kpi+ K. pneumoniae and indicate that the presence of Kpi may explain the success of the ST-15 clone. Disrupting bacterial adherence to the intestinal surface could potentially target gastrointestinal colonization., This research was supported by Projects p-01216A and IJCI-2016-29524 (to A.P.), funded by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Minestry of Economy and Competetiveness (MINECO), respectively. It was also supported by Projects PI11/01034 (to M.P.), PI14/00059 and PI17/1482 (to M.P. and A.B.), and PI18/00501 (to G.B.), included in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 and funded by the Instituto de Salud Carlos III (ISCIII) and Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) cofinanced by European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014-2020. Grant BFU2016-77835-R of the MINECO (to A.R.) also supported this research. E.G. was financially supported by the SEIMC project. J.C.V.-U. was financially supported by the PFIS (Contratos Predoctorales de Formación en Investigación en Salud) program (F18/00315); J.A.V. was financially supported by IN607A 2016/22; M.M.-G. was financially supported by a Clara Roy grant (SEIMC); A.B. was financially supported by the Miguel Servet program (ISCIII, Spain); B.K.R.-J. was financially supported by Marie S. Curie Action SaPhaDe project (MSCA-IF-GF-836754); and A.P. was financially supported by the Juan de la Cierva program (MINECO, IJCI-2016-29524), Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica; p-01216A, Xunta de Galicia; IN607A 2016/22
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Diagnostic tool for surveillance, detection and monitoring of the high-risk clone K. pneumoniae ST15

  • Gato, Eva
  • Rodiño-Janeiro, Bruno Kotska
  • Gude, María José
  • Fernández-Cuenca, Felipe
  • Pascual, Álvaro
  • Fernández, Anabel María Viña
  • Pérez, A.
  • Bou, Germán
[Background] The global spread of Klebsiella pneumoniae ST15, causing multi-continental outbreaks, contributes to the movement of resistance genes between clones increasing the antimicrobial resistance crisis. The genomic traits providing it with the ability to outcompete other bacteria and cause epidemics remain unclear., [Aim] To identify the specific genomic traits of K. pneumoniae ST15 to develop a diagnostic test., [Methods] An outbreak caused by K. pneumoniae occurred in Hospital A Coruña, Spain. Antimicrobial susceptibility analysis and molecular typing (PGFE and MLST) were performed. One isolate of each sequence type was selected for whole-genome sequencing analysis. Comparative analysis of genomes was performed using RAST. BLASTn was used to evaluate the presence of the fhaC and kpiD genes. Two hundred and ninety-four K. pneumoniae from a Spanish nationwide collection were analysed by PCR., [Findings] Genotyping showed that 87.5% of the isolates tested belonged to a clone with a unique PFGE pattern which corresponded to ST15. Comparative genomic analysis of the different STs enabled us to determine the specific genomic traits of K. pneumoniae ST15. Two adherence-related systems (Kpi and KpFhaB/FhaC) were specific markers of this clone. Multiplex-PCR analysis with kpiD and fhaC oligonucleotides revealed that K. pneumoniae ST15 is specifically detected with a sensitivity of 100% and a specificity of 97.76%. The PCR results showed 100% concordance with the MLST and whole-genome sequencing data., [Conclusion] K. pneumoniae ST15 possesses specific genomic traits that could favour its dissemination. They could be used as targets to detect K. pneumoniae ST15 with high sensitivity and specificity., This work was supported by projects PI18/00501 (awarded to G.B.), p-01216A and IJCI-2016-29524 (awarded to A.P.), funded by the Instituto de Salud Carlos III, Spanish Society of Infectious Diseases and Clinical Microbiology and Spanish Ministry of Economy, Industry and Competitiveness (MEIC). A.P. and E.G. are supported by the Miguel Servet (CP22CIII-00007) and Sara Borrel programs, respectively, of the Instituto de Salud Carlos III, Spain., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines

  • Fuentes-Valverde, Víctor
  • García, Patricia
  • Candela, Ana
  • Santamarina-Fernández, Rebeca
  • Avendaño-Ortiz, José
  • Martínez-Alonso, Emma
  • Oviaño, Marina
  • Cantón, Rafael
  • Arenas, Jesús
  • Moscoso, Miriam
  • Bou, Germán
Introduction: Pseudomonas aeruginosa is a highly adaptable Gram-negative bacterium causing severe respiratory infections, particularly in vulnerable populations. The rise of antimicrobial resistance highlights the urgent need for effective vaccines. We previously developed a live-attenuated vaccine candidate, PAO1 ΔmurI Δalr ΔdadX, a genetically stable double auxotrophic strain that exhibited dose-dependent reactogenicity upon intranasal administration in mice, likely due to lipid A component of lipopolysaccharide (LPS). Methods: To reduce LPS-associated toxicity while preserving immunogenicity, we engineered novel strains by inactivating genes involved in lipid A biosynthesis (htrB1, htrB2) or modification (pagP, pagL). Lipid A structural modifications were confirmed by MALDI-TOF MS. Mutants were evaluated for Toll-like receptor 4 (TLR4) activation, virulence attenuation, and their ability to induce immune responses and protection in an acute pneumonia model. Results: All engineered strains displayed modified lipid A structures. Mutations in htrB1 and htrB2 reduced TLR4 activation and significantly attenuated virulence following intraperitoneal challenge in mice. Inactivation of pagL resulted in minimal attenuation, whereas pagP inactivation led to marked attenuation without altering TLR4 activation. In the acute pneumonia model, all mutants elicited robust systemic and mucosal immune responses, and conferred strong protection, despite transient weight loss following intranasal administration. Discussion: Targeted lipid A modification represents an effective strategy to reduce in vitro reactogenicity while preserving immunogenicity in live-attenuated P. aeruginosa vaccine candidates. Although further optimization may minimize residual in vivo effects, these findings support the potential of engineered strains as vaccine candidates for preventing respiratory infections caused by P. aeruginosa.